7 Best Stocks for the Next 30 Days

Get them in a free Special Report, and get more Zacks Insights in our free e-newsletter, Profit from the Pros. Every issue includes a fresh Zacks #1 Bull Stock of the Day.

Close This Panel X

Are you a new Zacks Member or a visitor to Zacks.com?

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Stocks on the Move 05/21/2013

Company Name Symbol %Change
SCIENTIFIC L SCIL
8.00%
NATUS MEDICA BABY
6.11%
SUMMER INFAN SUMR
6.02%
RADIANT LOGI RLGT
5.32%
NEW ORIENTAL EDU
4.51%

Westamerica Bancorp (WABC)

by Zacks Equity Research

September 04, 2012 | Comments : 0 Recommended this article: (0)

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Westamerica Bancorp's (WABC) second quarter 2012 earnings were in line with the Zacks Consensus Estimate. Results were adversely impacted by lower revenue. Reduced non-interest expenses, improving credit quality and stable capital ratios were the positives.

Due to challenging economic environment, net interest margin (NIM) in the second quarter declined to 4.89% from 5.38% in the prior-year period. We believe that the slow economic recovery and the Federal Reserve s decision to keep short-term interest rates low will keep NIM under pressure in the upcoming quarters.

Our six-month target price of $43.00 equates to about 14.3x the Zacks Consensus Estimate for 2012. Combined with the $1.48 per share annual dividend, this price target implies an expected negative return of 7.0% over that period, which is consistent with our long-term Underperform recommendation.

Read the full reports :

Email Print Share Rate Pos Rate Neg

Read/Post Comments (0) | Recommended this article (0)

Please login to Zacks.com or register to post a comment.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.